NASDAQ:ACIU - Nasdaq - CH0329023102 - Common Stock - Currency: USD
NASDAQ:ACIU (2/21/2025, 8:00:00 PM)
2.65
-0.01 (-0.38%)
The current stock price of ACIU is 2.65 USD. In the past month the price decreased by -1.85%. In the past year, price decreased by -22.97%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
AC IMMUNE SA
EPFL Innovation Park, Building B
Lausanne VAUD 1015 CH
CEO: Andrea Pfeifer
Employees: 147
Company Website: https://www.acimmune.com/
Investor Relations: https://ir.acimmune.com/
Phone: 41213459121
The current stock price of ACIU is 2.65 USD. The price decreased by -0.38% in the last trading session.
The exchange symbol of AC IMMUNE SA is ACIU and it is listed on the Nasdaq exchange.
ACIU stock is listed on the Nasdaq exchange.
10 analysts have analysed ACIU and the average price target is 10.2 USD. This implies a price increase of 284.91% is expected in the next year compared to the current price of 2.65. Check the AC IMMUNE SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AC IMMUNE SA (ACIU) has a market capitalization of 262.19M USD. This makes ACIU a Micro Cap stock.
AC IMMUNE SA (ACIU) currently has 147 employees.
AC IMMUNE SA (ACIU) has a resistance level at 2.66. Check the full technical report for a detailed analysis of ACIU support and resistance levels.
The Revenue of AC IMMUNE SA (ACIU) is expected to grow by 80.09% in the next year. Check the estimates tab for more information on the ACIU EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ACIU does not pay a dividend.
AC IMMUNE SA (ACIU) will report earnings on 2025-03-12, after the market close.
AC IMMUNE SA (ACIU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.46).
The outstanding short interest for AC IMMUNE SA (ACIU) is 1.73% of its float. Check the ownership tab for more information on the ACIU short interest.
ChartMill assigns a fundamental rating of 3 / 10 to ACIU. ACIU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ACIU reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS increased by 50% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -16.32% | ||
ROE | -30.62% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 88% to ACIU. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 14.55% and a revenue growth 80.09% for ACIU